Zai Lab Q1 product revenue $62.8M, up 36% YoY; net loss narrows to $49.1M

Zai Lab Ltd

2023-Q1 EPS reported -$0.05 revenue$62,797,000

Product revenue $62.8M (+36% YoY); ZEJULA $42.7M (+44% YoY); Optune $13.3M; QINLOCK $1.3M; NUZYRA $5.5M.
Net loss $49.1M ($0.05 per share) vs $82.4M loss ($0.09 per share) in Q1 2022.
Cash $931.4M at March 31, 2023; R&D expense $48.5M, SG&A $62.5M.
Josh Smiley promoted to President and COO effective April 1, 2023.
Entered global license with MediLink for DLL3 ADC (ZL-1310) to expand lung cancer and oncology pipeline.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zai Lab Ltd reported the first quarter of 2023 results: revenue $62.8 million.

Period: the first quarter of 2023
Revenue: $62.8 million
Result: reported results

Exact text from the filing

Total product revenue of $62.8 million for the first quarter of 2023

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Zai Lab Ltd filing history →

Source: SEC EDGAR

accession 0001628280-23-016803

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.